سوق اختبار تعاطي المخدرات في نقطة الرعاية في أمريكا الشمالية – اتجاهات الصناعة والتوقعات حتى عام 2031

تحليل حجم سوق اختبار تعاطي المخدرات في نقطة الرعاية في أمريكا الشمالية

إن السوق مدفوع بزيادة الوعي والتركيز على الوقاية من تعاطي المخدرات وإدارتها، جنبًا إلى جنب مع الحاجة المتزايدة إلى اختبارات سريعة ودقيقة للمخدرات في بيئات متنوعة. تشمل العوامل الرئيسية التي تغذي نمو السوق ارتفاع معدلات تعاطي المخدرات، والمتطلبات التنظيمية الصارمة لاختبارات المخدرات في أماكن العمل، والتقدم في تقنيات اختبار نقطة الرعاية التي توفر دقة محسنة وراحة للمستخدم. بالإضافة إلى ذلك، يساهم الانتشار المتزايد لاضطرابات تعاطي المخدرات عبر مختلف التركيبة السكانية في الطلب على حلول اختبار المخدرات الفعالة والمتاحة.

يشتمل سوق اختبار تعاطي المخدرات في نقطة الرعاية في أمريكا الشمالية على مجموعة من التقنيات والحلول التشخيصية المصممة للكشف عن وجود مواد غير مشروعة أو مخدرات خاضعة للرقابة في نظام الفرد في موقع الرعاية، بدلاً من بيئة المختبر التقليدية. توفر هذه الاختبارات نتائج سريعة وفورية، وهي ضرورية لاتخاذ القرارات والتدخل في الوقت المناسب في مختلف البيئات مثل المرافق الطبية وغرف الطوارئ وأماكن العمل وحتى في البيئات المنزلية. يشمل السوق أجهزة ومجموعات اختبار للكشف عن المخدرات في البول واللعاب والدم والعينات البيولوجية الأخرى.

تحلل شركة Data Bridge Market Research أن سوق اختبار تعاطي المخدرات في نقطة الرعاية (POC) في أمريكا الشمالية من المتوقع أن يصل إلى 804.35 مليون دولار أمريكي بحلول عام 2031 من 558.70 مليون دولار أمريكي في عام 2023، بنمو بمعدل نمو سنوي مركب قدره 4.8٪ في الفترة المتوقعة من 2024 إلى 2031.

تعريف السوق

يشير اختبار تعاطي المخدرات في نقطة الرعاية إلى طرق الفحص السريع المستخدمة للكشف عن وجود المخدرات أو نواتج أيضها في نظام الشخص في موقع الرعاية، مثل العيادات أو غرف الطوارئ. توفر هذه الاختبارات نتائج سريعة، مما يتيح اتخاذ القرار في الوقت المناسب للعلاج أو التدخل. عادةً ما ينطوي اختبار نقطة الرعاية على عينات من البول أو اللعاب أو الدم، وهو ضروري لمراقبة تعاطي المواد، وضمان سلامة المريض، وتسهيل الوصول إلى خدمات الدعم المناسبة

ديناميكيات سوق اختبار تعاطي المخدرات في نقطة الرعاية في أمريكا الشمالية

يتناول هذا القسم فهم محركات السوق والمزايا والفرص والقيود والتحديات. ويتم مناقشة كل هذا بالتفصيل على النحو التالي:

السائقين

• ارتفاع حالات تعاطي المخدرات

لقد تزايد تعاطي المخدرات التي تشمل المواد الأفيونية والقنب والأمفيتامينات على المستوى الإقليمي، مما أدى إلى خلق أزمة صحية عامة تتطلب حلولاً فورية وقابلة للتطوير. يعتمد مقدمو الرعاية الصحية ووكالات إنفاذ القانون وأصحاب العمل بشكل متزايد على اختبارات المخدرات في نقاط الرعاية لأنها توفر الكشف السريع والدقيق وفي الموقع، وهو أمر بالغ الأهمية في إدارة عواقب تعاطي المخدرات.

في مجال الرعاية الصحية، تعد الحاجة إلى الكشف السريع عن تعاطي المخدرات أمرًا ضروريًا لتقديم التدخلات في الوقت المناسب، وخاصة في حالات الطوارئ أو مراكز إعادة التأهيل. وفي إنفاذ القانون، تعمل القدرة على اختبار الأفراد في الموقع على تسريع عملية اتخاذ القرار وتعزيز الجهود الرامية إلى الحد من الجرائم المتعلقة بالمخدرات. وعلى نحو مماثل، تتبنى أماكن العمل اختبار المخدرات في مكان العمل للحفاظ على بيئة خالية من المخدرات، وتقليل المسؤولية، والامتثال لقواعد السلامة.

Technological advancements in POC testing devices further support the growing demand for rapid, reliable testing methods. These devices are becoming more portable, user-friendly, and capable of detecting a wide range of substances, making them ideal for use in non-laboratory settings.

For instance,

• In January 2024, according to an article published by NCBI, Opioid Use Disorder (OUD) affects over 16 million people worldwide, including 2.1 million in the U.S., leading to more than 120,000 deaths regionally each year. The prevalence of opioid use and dependency is high, with up to 50% of long-term opioid users meeting OUD criteria. The rising incidence of opioid-related issues drives the need for effective drug testing solutions, thereby fuelling growth in the North America Point-of-Care (POC) drug abuse testing market
• In August 2023, according to an article published by WHO, in 2019, approximately 600,000 deaths regionally were linked to drug use, with about 80% related to opioids. Of these, around 125,000 were due to opioid overdose, while non-fatal overdoses are significantly more common. The rise in opioid overdoses is attributed to increased opioid availability for chronic pain management and the presence of potent opioids on the illicit market. In the USA, drug overdose deaths totaled 70,630 in 2019, with synthetic opioids involved in about half of these cases.

Growth in Home and Parental Drug Testing Kits

The growing demand for easy-to-use, over-the-counter drug testing kits for home use reflects a strong consumer preference for privacy and convenience in monitoring substance use. Parents are increasingly adopting these kits to detect and prevent substance abuse among teenagers, while individuals are opting for self-testing options for personal reasons.

Technological advancements have led to the creation of more accurate, reliable, and user-friendly drug testing products, enabling consumers to perform tests privately at home without professional assistance. This convenience reduces the stigma associated with drug testing, fostering wider adoption of these solutions. Home testing kits are now more sensitive and capable of detecting a broad range of drugs, providing results that are comparable to those from laboratory tests.

Increased awareness of substance abuse and the easy availability of these kits through pharmacies and online platforms are contributing to market growth. The trend is further supported by a growing preference for non-invasive sample collection methods, such as saliva or urine tests, which are simple to use at home.

For instance,

• In November 2023, according to an article published by DNA Forensics Laboratory Pvt. Ltd., in recent years, at-home drug testing kits have become increasingly popular due to their convenience and ease of access. These kits enable individuals to conduct drug tests privately at home, typically including test strips or collection devices along with clear instructions for sample collection and result interpretation. This trend towards home testing highlights the "growth in home and parental drug testing kits" and drives the demand for such products. The growing preference for private and convenient drug testing solutions propels the expansion of the North America Point-of-Care (POC) drug abuse testing market.

In conclusion, the rising demand for home and parental drug testing kits is driving significant growth in the POC drug abuse testing market by offering consumers private, convenient, and reliable options for substance abuse monitoring, fueling expansion in this segment.

Opportunity

• Growing Awareness and the Campaign for Drug Testing

The increasing awareness surrounding the dangers of drug abuse, coupled with robust public health campaigns and government support, presents a significant opportunity for growth in the North America Point-of-Care (POC) drug abuse testing market. As society becomes more cognizant of the detrimental impacts of substance abuse, there is a growing demand for accessible and effective testing solutions. Public health campaigns, often spearheaded by governmental and non-governmental organizations, play a crucial role in educating communities about the importance of early detection and intervention. These initiatives not only amplify the visibility of drug abuse issues but also advocate for the use of point-of-care testing as a preventive measure. Furthermore, government support through funding and policy-making enhances the accessibility of POC drug testing solutions by promoting regulatory frameworks that facilitate the adoption of these technologies in various settings, including workplaces, schools, and public health programs. The combination of heightened awareness and strategic support fosters an environment conducive to market expansion, driving innovation and increasing the availability of advanced testing solutions to address the evolving needs of society.

• In December 2023, according to the article published by the Greater London Authority, UK government allocated USD 1.54 million to this mission, focusing on testing for 14 different drugs with the rising awareness and proactive government initiatives in the UK have led to the implementation of random mandatory drug testing for individuals released from prison, aiming to reduce crime rates. This move underscores the nation's commitment to tackling substance abuse and its impact on criminal behavior, reflecting broader efforts to enhance public safety and well-being.
• In July 2021, according to the article published by Commonwealth of Australia and the Department of Health and Aged Care, the Australian government launched the National Ice Action Strategy, which included significant investments to enhance Point-of-Care (POC) drug abuse testing. This initiative aimed to curb the growing use of methamphetamines, commonly known as "ice," by providing law enforcement and healthcare providers with more accessible and accurate drug testing tools. The strategy also focused on expanding the availability of POC testing in remote and rural areas, ensuring that communities across the country could benefit from timely and effective drug detection and intervention measures.

Hence, the convergence of growing awareness, active public health campaigns, and strong government support is poised to significantly benefit the North America Point-of-Care (POC) drug abuse testing market. This dynamic environment not only promotes the adoption of drug testing technologies but also encourages the development of more sophisticated and accessible solutions. As these factors continue, the future of POC drug abuse testing looks promising, with enhanced opportunities for innovation, broader market reach, and improved public health outcomes.

Restraint/Challenge

• High Costs Associated with the Testing

The complexity of developing reliable and accurate POC drug abuse tests often requires advanced technology, specialized materials, and rigorous validation processes, all of which contribute to elevated production costs. These costs are further compounded by stringent regulatory requirements, as ensuring compliance with international standards demands extensive testing, quality control, and documentation, adding to the overall expense. Additionally, the need for consistent research and development to keep pace with emerging drug abuse patterns and to enhance the sensitivity and specificity of these tests drives up the costs even more. For healthcare providers, the high upfront investment required to integrate these testing solutions into their practices can be prohibitive, particularly for smaller clinics or organizations with limited budgets. This financial burden can deter the adoption of POC drug abuse testing despite its potential benefits in terms of speed and convenience. The situation is exacerbated in low- and middle-income countries, where healthcare budgets are already strained, and the added cost of POC testing can be a barrier to implementation, limiting the market's expansion into these regions. Moreover, the high cost can lead to disparities in healthcare access, as only well-funded institutions may be able to afford these advanced testing methods, leaving vulnerable populations without adequate testing and care. This challenge is not only a financial one but also an ethical issue, as the inability to provide affordable testing solutions undermines the efforts to combat drug abuse on a broader scale.

 For instance,

• In May 2023, according to an article published by the National Library of Medicine, POC testing was costlier performed on an individual basis when compared to traditional laboratory testing due to the single-use nature of most POCT devices, which adds to the overall expenses
• In January 2024, according to an article published by Checkr., the cost of drug testing for comprehensive laboratory panels can exceed USD 500. Onsite tests typically range from USD 20 to USD 40, but the need for lab confirmation can drive prices up, starting at USD 50 and varying based on the test type and substances screened. High volumes of tests might reduce the average cost per test, but the overall expense can still be substantial

Hence, the high cost of POC drug abuse testing creates significant barriers to its broader adoption, limiting accessibility, especially in resource-constrained regions. This financial challenge not only hampers market growth but also exacerbates healthcare inequalities, preventing many from receiving timely and effective drug abuse testing, and is expected to act as a challenge for market growth in the future.

Recent Developments

• In August 2024, Abbott announced a North America partnership with Medtronic on August 7, 2024, to integrate Abbott's advanced FreeStyle Libre Continuous Glucose Monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aimed to enable automatic insulin adjustments and improve diabetes management, benefiting over 11 million people worldwide. Financial terms were undisclosed
• In March 2024, Abbott extended its partnership with Real Madrid and the Real Madrid Foundation through the 2026-2027 season, continuing as their North America health sciences and nutrition partner. Since 2021, Abbott provided over 25,000 hours of nutrition education and screened more than 3,000 children for malnutrition
• In August 2023, SSM Health, Siemens Healthineers partner to advance health equity and empower workforce development in underserved communities. The partnership with SSM Health benefits Siemens Healthineers by expanding its market presence, increasing visibility of its technology, fostering long-term growth, and enhancing its reputation in the healthcare sector
• In February 2024, Roche entered into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics. The collaboration provides Roche with PathAI’s advanced AI technology for improving companion diagnostics. It ensures exclusive, tailored solutions and accelerates algorithm development while allowing Roche to continue developing its own diagnostics
• In November 2023, Roche launched next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges. Roche’s next-generation qPCR system boosts its market position, meets clinical and public health needs, and opens new revenue opportunities while showcasing its commitment to innovation

North America Point-of-Care (POC) drug abuse testing market Scope

The North America Point-of-Care (POC) drug abuse testing market is segmented into eight notable segments based on drug type, products, prescription, sample type, testing type, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Drug Type

• Amphetamines
•  Opiates
•  Cannabinoids
•  Cocaine
•  Barbiturates
•  Benzodiazepines
•  Methadone
•  Phencyclidine
•  Tricyclic Antidepressants
•  Others

On the basis of drug type, the market is segmented into amphetamines, cannabinoids, opiates, cocaine, benzodiazepines, barbiturates, phencyclidine, methadone, tricyclic antidepressants, and others.

Products

• Devices
• Consumables and Accessories

On the basis of products, the market is segmented into devices and consumables and accessories.

Prescription

• Over the Counter Testing
• Prescription-Based Testing

On the basis of prescription mode, the market is segmented into prescription-based testing, and over the counter testing.

Sample Type

• Urine
•  Saliva
•  Blood
•  Hair
•  Breath
•  Others

On the basis of sample type, the market is segmented into urine, saliva, blood, hair, breath, and others.

Testing Type

• Random Testing
•  Post-Incident Testing
•  Abstinence Testing

On the basis of testing type, the market is segmented into random testing, post-incident testing, and abstinence testing.

Application

• Medical Screening
•  Workplace Screening
•  Law Enforcement and Criminal Justice
•  Pain Management
•  Substance Abuse Treatment and Rehabilitation
•  Parental or Home Drug Testing
•  Sports and Athletics Testing
•  Drug Screening in Schools and Educational Institutions
•  Others

On the basis of application, the market is segmented medical screening, workplace screening, law enforcement and criminal justice, pain management, substance abuse treatment and rehabilitation, parental or home drug testing, sports and athletics testing, drug screening in schools and educational institutions, and others.

End User

• Healthcare Facilities
•  Employers
•  Government Institutes
•  Others

On the basis of end user, the market is segmented into healthcare facilities, employers, government institute, and others.

Distribution Channel

• Direct Tender
•  Retail Sales
•  Others

On the basis of distribution channel, the market is segmented into direct tender, retails sales, and others.

North America Point-of-Care (POC) Drug Abuse Testing Market Regional Analysis/Insights

North America Point-of-Care (POC) drug abuse testing market is analyzed, and market size insights and trends are provided by based on drug type, products, prescription, sample type, testing type, application, end user, distribution channel as referenced above.

The countries covered in this market report are U.S., Canada, and Mexico.

من المتوقع أن تهيمن الولايات المتحدة على سوق أمريكا الشمالية بسبب عوامل مثل العدد الكبير من السكان، والإنفاق المرتفع على الرعاية الصحية، ونظام الرعاية الصحية المتطور، وصناعة الأدوية الواسعة النطاق، والوعي الواسع النطاق لدى المستهلكين والقدرة على الوصول إلى علاجات القروح الباردة.

كما يوفر قسم الدولة في التقرير عوامل التأثير الفردية على السوق والتغيرات في تنظيم السوق التي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. نقاط البيانات مثل تحليل سلسلة القيمة المصب والمصب، والاتجاهات الفنية وتحليل قوى بورتر الخمس، ودراسات الحالة هي بعض المؤشرات المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود وتوافر العلامات التجارية الإقليمية والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية، وتأثير التعريفات الجمركية المحلية وطرق التجارة أثناء تقديم تحليل توقعات لبيانات الدولة.   

تحليل حصة سوق اختبار تعاطي المخدرات في نقطة الرعاية (POC) في أمريكا الشمالية في المشهد التنافسي

يوفر المشهد التنافسي لسوق اختبار تعاطي المخدرات في نقطة الرعاية في أمريكا الشمالية تفاصيل حسب المنافس. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، والحضور الإقليمي، ومواقع الإنتاج والمرافق، والقدرات الإنتاجية، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركات على سوق اختبار تعاطي المخدرات في نقطة الرعاية في أمريكا الشمالية.

بعض اللاعبين الرئيسيين العاملين في سوق اختبار تعاطي المخدرات في نقطة الرعاية (POC) في أمريكا الشمالية هم Abbott Laboratories و Quest Diagnostics Incorporated و Thermo Fisher Scientific، Inc. و Bio-rad Laboratories، inc. و Agilent Technologies و Advacare Pharma و Cliawaived inc. من بين آخرين.

SKU-72873